All In Biotech

Drug Trial Radar · NCT02603432

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY

Last checked: Nov 20, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

700

Actual

Start

Apr 25, 2016

Primary completion

Oct 21, 2019

Study completion Mar 28, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.

Conditions

  • Urothelial Cancer

Interventions

  • AvelumabBiological

    1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles

  • Best Supportive CareOther

    BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.

  • Following the planned interim analysis for this study: AvelumabBiological

    1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization to discontinuation from the study, death or date of censoring, whichever occurred first (for a maximum duration of 41 months)

Locations

382 sites in 29 countries. Site status is shown where the registry gives one.

  • Anschutz Cancer Center Pavilion Pharmacy

    Aurora, Colorado

  • University of Colorado Cancer Center

    Aurora, Colorado

  • University of Colorado Denver, CTO (CTRC)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

    Aurora, Colorado

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

  • Cleveland Clinic Taussing Cancer Center

    Cleveland, Ohio

  • Cleveland Clinic Taussing Cancer Center

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Cleveland Clinic Taussing Cancer Center

    Cleveland, Ohio

  • Inova Schar Cancer Institute Infusion Pharmacy

    Fairfax, Virginia

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • University of Washington Medical Center

    Seattle, Washington

  • Fundación CENIT para la Investigación en Neurociencias

    CABA, Argentina

  • GP Diagnostico SRL

    La Rioja, Argentina

  • Hospital Regional Dr. Enrique Vera Barros

    La Rioja, Argentina

  • Instituto del Diagnostico

    La Rioja, Argentina

  • Centro Oncologico Riojano Integral (Cori)

    La Rioja, Argentina

  • Centro de Investigacion Pergamino S.A.

    Pergamino, Buenos Aires, Argentina

  • Slade Health

    Mount Waverley, Australia

  • Macquarie Heart

    New South Wales, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Concord Hospital

    Concord, New South Wales, Australia

  • Dubbo Base Hospital

    Dubbo, New South Wales, Australia

  • Ramsay Pharmacy

    Kogarah, New South Wales, Australia

  • St George Private Hospital

    Kogarah, New South Wales, Australia

  • Epic Pharmacy

    Lismore, New South Wales, Australia

  • North Coast Radiology St Vincents

    Lismore, New South Wales, Australia

  • Northern Rivers Pathology Service

    Lismore, New South Wales, Australia

  • St Vincent's Pathology Lismore

    Lismore, New South Wales, Australia

  • Macquarie Medical Imaging

    Macquarie University, New South Wales, Australia

  • Macquarie University Hospital Pharmacy

    Macquarie University, New South Wales, Australia

  • Macquarie University

    Macquarie University, New South Wales, Australia

  • The Murwillumbah Hospital

    Murwillubah, New South Wales, Australia

Showing 40 of 382 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.